DE69231469T2 - Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen - Google Patents

Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen

Info

Publication number
DE69231469T2
DE69231469T2 DE69231469T DE69231469T DE69231469T2 DE 69231469 T2 DE69231469 T2 DE 69231469T2 DE 69231469 T DE69231469 T DE 69231469T DE 69231469 T DE69231469 T DE 69231469T DE 69231469 T2 DE69231469 T2 DE 69231469T2
Authority
DE
Germany
Prior art keywords
gentisic acid
proteins
labeled peptides
gentisyl alcohol
stabilize
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69231469T
Other languages
English (en)
Other versions
DE69231469D1 (de
Inventor
Edward A Deutsch
Wilhelmus Theodorus Goedemans
Jong Martinus Theodorus De
Kathleen M Miller
James W Brodack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mallinckrodt Inc
Original Assignee
Mallinckrodt Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mallinckrodt Medical Inc filed Critical Mallinckrodt Medical Inc
Application granted granted Critical
Publication of DE69231469D1 publication Critical patent/DE69231469D1/de
Publication of DE69231469T2 publication Critical patent/DE69231469T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DE69231469T 1991-08-29 1992-07-31 Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen Expired - Lifetime DE69231469T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75182591A 1991-08-29 1991-08-29
PCT/US1992/006429 WO1993004702A1 (en) 1991-08-29 1992-07-31 Use of gentisic acid or gentisyl alcohol for stabilising radiolabeled peptides and proteins

Publications (2)

Publication Number Publication Date
DE69231469D1 DE69231469D1 (de) 2000-10-26
DE69231469T2 true DE69231469T2 (de) 2001-01-25

Family

ID=25023648

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69231469T Expired - Lifetime DE69231469T2 (de) 1991-08-29 1992-07-31 Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen

Country Status (11)

Country Link
US (1) US5384113A (de)
EP (1) EP0600992B1 (de)
JP (1) JP3853354B2 (de)
AT (1) ATE196428T1 (de)
AU (1) AU2462592A (de)
CA (1) CA2113995C (de)
DE (1) DE69231469T2 (de)
DK (1) DK0600992T3 (de)
ES (1) ES2150916T3 (de)
GR (1) GR3035067T3 (de)
WO (1) WO1993004702A1 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4897255A (en) * 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5985240A (en) * 1989-08-09 1999-11-16 Rhomed Incorporated Peptide radiopharmaceutical applications
GB9004017D0 (en) * 1990-02-22 1990-04-18 Krenning Eric P Improvements in or relating to organic compounds
CA2123144A1 (en) * 1993-05-10 1994-11-11 David Bodmer Stabilisation of pharmacologically active compounds in sustained release compositions
US5830431A (en) * 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US20010055563A1 (en) 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997033580A1 (en) * 1996-03-11 1997-09-18 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5859043A (en) * 1996-06-11 1999-01-12 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Method for maintaining kidney function during surgery or severe trauma under general anesthesia
AUPO066096A0 (en) * 1996-06-26 1996-07-18 Peptide Delivery Systems Pty Ltd Oral delivery of peptides
US6027710A (en) * 1996-09-18 2000-02-22 Nihon Medi-Physiscs Co., Ltd. Radiation-protecting agent
US6468971B1 (en) 1997-03-05 2002-10-22 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Maintaining kidney function during surgery or trauma
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2341489A1 (en) * 1998-09-25 2000-04-06 Mallinckrodt, Inc. Somatostatin receptor radioligand with increased uptake
WO2001000637A1 (en) * 1999-06-29 2001-01-04 Mallinckrodt Inc. Group (vii) transition-metal complexes with multidentate aminopolycarboxylate ligands and a kit for producing them
AU2002218751A1 (en) * 2000-07-06 2002-01-21 Bristol-Myers Squibb Pharma Company Stable radiopharmaceutical compositions
US6989138B2 (en) 2000-10-24 2006-01-24 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers and hydrophilic 6-hydroxy chromans
US6881396B2 (en) * 2000-10-24 2005-04-19 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic 6-hydroxy-chromans
US6902718B2 (en) * 2000-10-24 2005-06-07 Diatide, Inc. Stabilization of radiopharmaceutical compositions using hydrophilic thioethers
WO2002067859A2 (en) * 2001-02-26 2002-09-06 Bristol-Myers Squibb Pharma Company Ascorbic acid analogs for metalloradiopharmaceuticals
US6567492B2 (en) 2001-06-11 2003-05-20 Eastern Isotopes, Inc. Process and apparatus for production of F-18 fluoride
US7238338B1 (en) * 2001-06-22 2007-07-03 Triumf System and method for the large scale labeling of compounds with radiohalogens
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
WO2004043497A1 (en) 2002-11-05 2004-05-27 Ion Beam Applications S.A. Stabilzation of radiopharmceuticals labeled with 18-f
US7018614B2 (en) 2002-11-05 2006-03-28 Eastern Isotopes, Inc. Stabilization of radiopharmaceuticals labeled with 18-F
CN100418585C (zh) * 2003-07-24 2008-09-17 伯拉考成像股份公司 稳定的放射性药物组合物及制备方法
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
CN101198359B (zh) * 2005-06-14 2011-06-22 日本医事物理股份有限公司 放射性诊断成像剂
GB0514087D0 (en) 2005-07-11 2005-08-17 Ge Healthcare Ltd Stabilised radiopharmaceutical compositions
AU2008324186B2 (en) * 2007-11-07 2014-02-13 Ge Healthcare Bv Stabilization of radiopharmaceuticals
WO2009086062A1 (en) * 2007-12-21 2009-07-09 Lyotropic Therapeutics, Inc. Stabilized formulations of peptides and proteins
EP2257315B1 (de) 2008-02-29 2019-10-23 Lantheus Medical Imaging, Inc. Kontrastmittel für anwendungen einschliesslich perfusionsbildgebung
US9687571B2 (en) 2009-04-15 2017-06-27 Lantheus Medical Imaging, Inc. Stabilization of radiopharmaceutical compositions using ascorbic acid
PT2534136T (pt) 2010-02-08 2017-12-15 Lantheus Medical Imaging Inc Métodos para sintetizar agentes de imagiologia, e seus intermediários
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
GB201504064D0 (en) * 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
KR102445956B1 (ko) * 2016-11-04 2022-09-22 클라리티 파마슈티컬스 리미티드 방사선 요법 및 진단 영상용 제형
US10596276B2 (en) 2018-07-25 2020-03-24 Advanced Accelerator Applications (Italy) S.R.L. Stable, concentrated radionuclide complex solutions
CN114835690B (zh) * 2022-07-04 2022-09-27 北京先通国际医药科技股份有限公司 含化合物i的液体组合物的制备方法、及在心肌灌注pet显像中的用途
CN115015441B (zh) * 2022-07-14 2023-08-18 原子高科股份有限公司 一种测定镥[177Lu]氧奥曲肽注射液中稳定剂含量的方法
WO2024036372A1 (en) * 2022-08-16 2024-02-22 Clarity Pharmaceuticals Limited Formulations for radiotherapy and diagnostic imaging and use thereof in treatment, diagnosis and imaging diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4497744A (en) * 1978-03-31 1985-02-05 Mallinckrodt, Inc. Gentisic acid salts as radiographic scanning agent stabilizers
US4232000A (en) * 1978-06-28 1980-11-04 The Procter & Gamble Company Radioactive scanning agents with stabilizer
US4229427A (en) * 1978-06-28 1980-10-21 The Procter & Gamble Company Radioactive scanning agents with hydroquinone stabilizer
US4232284A (en) * 1979-05-07 1980-11-04 Power Parts, Inc. Ignition coil and electrical connector therefor
US4440738A (en) * 1982-06-10 1984-04-03 Mallinckrodt, Inc. Stable radiographic imaging agents
US4504462A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4504463A (en) * 1982-06-10 1985-03-12 Mallinckrodt, Inc. Process for making a lyophilized product for use in skeletal imaging
US4707353A (en) * 1982-12-08 1987-11-17 Mallinckrodt, Inc. Radiographic imaging agents
US4510125A (en) * 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS59199636A (ja) * 1983-04-26 1984-11-12 Nippon Mejifuijitsukusu Kk 放射性診断剤
US4942231A (en) * 1984-05-24 1990-07-17 Mallinckrodt, Inc. Method of preparing a chlorinated, brominated, radio-brominated, iodinated and/or radioiodinated aromatic or heteroaromatic compound
EP0313712B1 (de) * 1987-10-30 1992-07-29 SORIN BIOMEDICA S.p.A. Stabile radiodiagnostische Präparate und ihre Herstellung
GB2239178B (en) * 1987-07-10 1991-11-27 Sandoz Ltd Somatostatin analogues for the treatment of breast cancer
MY106120A (en) * 1988-12-05 1995-03-31 Novartis Ag Peptide derivatives.
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5093105A (en) * 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats

Also Published As

Publication number Publication date
EP0600992A1 (de) 1994-06-15
JPH06510539A (ja) 1994-11-24
WO1993004702A1 (en) 1993-03-18
JP3853354B2 (ja) 2006-12-06
AU2462592A (en) 1993-04-05
DK0600992T3 (da) 2000-10-09
US5384113A (en) 1995-01-24
EP0600992B1 (de) 2000-09-20
ES2150916T3 (es) 2000-12-16
DE69231469D1 (de) 2000-10-26
GR3035067T3 (en) 2001-03-30
CA2113995C (en) 2003-04-22
ATE196428T1 (de) 2000-10-15
CA2113995A1 (en) 1993-03-18

Similar Documents

Publication Publication Date Title
DE69231469T2 (de) Verwendung von gentisinsäure oder gentisylalkohol zur stabilisierung von radio-markierten peptiden und proteinen
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
DK623186D0 (da) Polypeptid med vaevsplasminogen-aktivator-virkning
DE69224622T2 (de) Herstellung von prothrombinzeit-reagenzien aus rekombinantem menschlichem gewebefaktor und sythetischen phospholipiden
DE68929043T2 (de) Für androgen-rezeptor-protein kodierende dna
ATE110782T1 (de) Rekombinanter menschlicher endothelzellenwachstumsfaktor.
ATE80894T1 (de) Reinigung des natuerlichen kolonie-stimulierenden faktors-1.
HUP9900506A2 (hu) Protrombinszármazékok
DE68917837D1 (de) Peptid-Verbindungen.
ATE172108T1 (de) Verwendung von diglycerinestern gegen unreine haut
DE3687948T2 (de) Verfahren und nukleinsaeure zur herstellung von lecithin: cholestrinacyltransferase.
DE59406092D1 (de) Verwendung von carboxylgruppen enthaltenden umsetzungsprodukten von proteinen oder proteinhydrolysaten in wasch- und reinigungsmitteln
DK262986A (da) Peptidmateriale med thymushumoral aktivitet
ATE195322T1 (de) Verwendung von oberflächenaktiven substanzen zur stabilisierung von peptiden und proteinen zur radiopharmazeutischen verwendung
ATE218334T1 (de) Verwendung von gabapentin in der behandlung vonangst - und panikstörungen
ES2032812T3 (es) Vacuna.
DE59404726D1 (de) Angiogenin und/oder alpha1-microglobulin und/oder komplementfaktor d zur begrenzung der sekretion von proteinen
NL7007420A (en) Synthetic polypeptides - salmon calcitonin derivs. with pharmacodynamic properties

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 600992

Country of ref document: EP

Representative=s name: JOACHIM FECHNER, 53773 HENNEF, DE

R082 Change of representative

Ref document number: 600992

Country of ref document: EP

Representative=s name: ,

R071 Expiry of right

Ref document number: 600992

Country of ref document: EP